Results of Utility of Long-term Herceptin Use After Adjuvant Chemotherapy
http://www.cancernetwork.com/practic.../10165/1816904
Overall, the study shows that Herceptin is efficacious as an adjuvant treatment. Nevertheless, the result that extending the period between chemotherapy and the start of Herceptin to 1 to 3 years has a benefit for early breast cancer patients will need to be followed up with a controlled, randomized clinical trial. The optimal Herceptin duration of treatment is still not known and is the subject of ongoing clinical trials. Furthermore, as the author of the accompanying editorial mention, a 4-year follow up is still quite short for an adjuvant trial and it may still play out that concurrent chemotherapy and Herceptin treatment is a more effective strategy that chemotherapy followed by Herceptin in an adjuvant setting. |
All times are GMT -7. The time now is 11:59 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021